Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Elraglusib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Actuate's Pancreatic Cancer Drug Boosts Survival by 3 Months
    Actuate's Pancreatic Cancer Drug Boosts Survival by 3 Months

    03 Jun 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/asco-actuates-pancreatic-cancer-drug-boost-survival-3-months-phase-2-study

    FIERCE BIOTECH
    03 Jun 2025
    Share Share
    Actuate Share Ph2 Elraglusib Data In Metastatic Pancreatic Cancer
    Actuate Share Ph2 Elraglusib Data In Metastatic Pancreatic Cancer

    02 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/02/3091936/0/en/Actuate-Therapeutics-Shares-Highlights-from-KOL-Event-on-Positive-Topline-Elraglusib-Phase-2-Data-in-First-Line-Treatment-of-Metastatic-Pancreatic-Cancer.html

    GLOBENEWSWIRE
    02 Jun 2025
    Share Share
    Actuate Therapeutics Hosts KOL Event on Elraglusib Phase 2 Data
    Actuate Therapeutics Hosts KOL Event on Elraglusib Phase 2 Data

    07 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/07/3076061/0/en/Actuate-Therapeutics-to-Host-KOL-Event-on-Topline-Phase-2-Data-of-Elraglusib-in-Metastatic-Pancreatic-Ductal-Adenocarcinoma-During-ASCO-Annual-Meeting.html

    GLOBENEWSWIRE
    07 May 2025
    Share Share
    Elraglusib Shows Benefit In Metastatic Pancreatic Cancer
    Elraglusib Shows Benefit In Metastatic Pancreatic Cancer

    06 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/06/3074989/0/en/Actuate-Therapeutics-Announces-Statistically-Significant-Topline-Results-from-Global-Phase-2-Trial-of-Elraglusib-in-First-Line-Treatment-of-Metastatic-Pancreatic-Cancer.html

    GLOBENEWSWIRE
    06 May 2025
    Share Share
    Actuate to Present Elraglusib Phase 2 Data at 2025 ASCO Meeting
    Actuate to Present Elraglusib Phase 2 Data at 2025 ASCO Meeting

    23 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/23/3066581/0/en/Actuate-to-Present-Elraglusib-Phase-2-Topline-Data-at-the-2025-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html

    GLOBENEWSWIRE
    23 Apr 2025
    Share Share
    Actuate to Present Data on Elraglusib in Salivary Gland Carcinoma
    Actuate to Present Data on Elraglusib in Salivary Gland Carcinoma

    17 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/17/3063291/0/en/Actuate-to-Present-Promising-Data-on-Elraglusib-in-Advanced-Salivary-Gland-Carcinoma-at-the-AACR-Annual-Meeting-2025.html

    GLOBENEWSWIRE
    17 Apr 2025
    Share Share